SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 8, 2001
TANOX, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-30231 76-0196733
(State or other jurisdiction (Commission File No.) (I.R.S. Employer
of incorporation) Identification No.)
10301 STELLA LINK, SUITE 110, HOUSTON, TEXAS 77025-5497
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: 713-578-4000
1
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
Genentech, Inc. and Novartis Pharmaceuticals Corporation today issued a
statement regarding recent conversations with the U.S. Food and Drug
Administration (FDA) with respect to its review of the Biologics License
Application for Xolair(TM) (Omalizumab). A copy of their joint press release is
attached as an Exhibit hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1-- Press Release of Genentech, Inc. and Novartis Pharmaceuticals
Corporation issued on March 8, 2001.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 8, 2001 TANOX, INC.
By: Michael A. Kelly
----------------------
Michael A. Kelly
Vice President of Finance and CFO
3